Direct Compression Tablet Manufacture at High-Speed Rotary Presses

Direct compression of the amine API at production scale requires a pre-lubricated blend with controlled bulk density, residual moisture, and particle-size overlap between the active and brittle fillers. On high-speed rotary presses fitted with multipoint force monitoring, the blend is first passed through a 500 µm conical mill to break agglomerates, then mixed in a bin blender at 12 rpm to 18 rpm for 30–60 min. The compression event is run with precompression force between 2.0 kN and 5.0 kN and main compression force between 8.0 kN and 18.0 kN using B-tooling with tablet diameters from 6 mm to 12 mm. Ejection force is monitored at values below 1000 N to avoid picking and edge failure. Compression suites for hygroscopic amine salts are operated at 20–25 °C and 30–40% RH, with lower humidity applied when a sticking tendency is observed on the punch face. The governing batch-release standards include USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and USP <701> Disintegration; the manufacturing controls fall under 21 CFR 211.110 sampling and testing of in-process materials, while elemental impurity limits follow ICH Q3D. The formulation addition ratio is dose-dependent and is not a fixed release specification. For tablet core masses of 100 mg to 800 mg, the amine API commonly occupies 0.1 wt% to 25.0 wt% of the core; low-dose strength tablets containing 10 µg to 1 mg of amine API require a staged preblend at 1:10 to 1:100 API-to-excipient ratio before final dilution. Direct compression is most feasible when the amine API has a Carr index below 25 and a Hausner ratio below 1.35; otherwise capping or lamination occurs. Terminal product types include immediate-release film-coated tablets, uncoated scored tablets, and tablet cores intended for polymer film coating with weight gain of 1.5–3.5 wt%.

Capsule filling on a dosator configuration exposes low-dose segregation and plug density variability that is not observed in direct compression. The process begins with an ordered preblend of the amine API onto microcrystalline cellulose or lactose monohydrate carrier particles. The formulation addition ratio for low-dose capsules is typically 1:20 to 1:200 w/w API-to-excipient in the preblend, followed by dilution into the final capsule fill mass. The finished capsule fill mass ranges from 180 mg to 500 mg for capsule size 3 through 0, with the API dose per capsule established by the approved label claim rather than by a universal percentage. Batch release requires USP <905> Uniformity of Dosage Units and USP <711> Dissolution; capsule shell integrity and fill weight control are governed by 21 CFR 211.101 charge-in of components and 21 CFR 211.165 testing and release. On dosator machines, powder bed height is maintained between 100 mm and 150 mm inside the feed hopper, while dosator plunger displacement is set from 0.25 mm to 0.60 mm to produce plug densities from 0.60 g/mL to 0.85 g/mL. Tamping-pin machines require independent pin depth adjustment and pin count selection to control fill weight relative standard deviation below 2.0%. A production-scale bottleneck occurs when the amine API has a median particle size below 20 µm: flow through the dosator stem becomes intermittent unless flow aids or granulated API are used. Terminal product types include hard gelatin and HPMC capsules filled with powder blends or miniature granulates, with individual capsule masses verified by automated checkweighers.

What High-Shear Wet Granulation Parameters Prevent Amine API Demixing and Overgranulation?

High-shear wet granulation of the amine API is selected when direct compression cannot deliver sufficient content uniformity or when the active is to be embedded in a dense matrix for modified release. The process is run in a top-drive high-shear mixer with impeller tip speed from 3 m/s to 8 m/s and chopper speed from 1500 rpm to 3000 rpm. Purified water or a binder solution is delivered at 5–15 g/min/kg of dry blend through a spray nozzle positioned above the moving powder mass. The endpoint is controlled by torque, target 8–12 N·m, rather than by fixed time alone, because the amine API can shift granule size distribution when the torque plateau is exceeded. In-process moisture after wet massing typically ranges from 10 wt% to 20 wt%, and the dried granulate is specified with loss on drying between 1.0 wt% and 2.5 wt%. The formulation addition ratio of the amine API in the dried granulate is generally 5 wt% to 40 wt%, with binder solids such as povidone or hypromellose at 1.5–5.0 wt% of the dry granulate mass. High-shear granulation is bounded by 21 CFR 211.111 time limits on intermediate storage and by ICH Q1A(R2) stability testing of the granulate when held before compression. Batch release standards include USP <905> and USP <711>; residual solvent and water content are confirmed against USP <731> or the applicable monograph. The wet granulate is dried in a fluid-bed dryer with inlet air temperature 50–70 °C, then sized through a conical mill fitted with 1.0–2.0 mm screens. Overgranulation is detected as bimodal particle-size distribution and higher dissolution variability, requiring reprocessing or blend adjustment. Terminal product types include oral granules filled into sachets, granules compressed into tablets, and granules filled into hard capsules. A critical operational boundary occurs when the amine API is a soluble salt: the active can migrate to the granule surface during drying, producing surface enrichment and subsequent picking on tablet punches unless the drying rate is controlled below the critical migration threshold.

When Roller Compaction Replaces Aqueous Granulation for Moisture-Sensitive Amine Salts

Roller compaction is the preferred dry granulation route for amine API forms that degrade or hydrate during aqueous wet massing. The process feeds a preblend through a roller compactor equipped with a vacuum deaeration unit and oscillating granulator. Roll pressure is maintained between 10 kN/cm and 30 kN/cm, roll gap between 1.5 mm and 3.0 mm, and roll speed between 2 rpm and 10 rpm. Ribbon density is the primary process control variable and is held from 0.8 g/cm³ to 1.2 g/cm³; lower-density ribbons increase fines, while excessive density reduces granule porosity and dissolution. The compacted ribbons are dry-milled through screens of 0.8–1.5 mm at mill rotor speed from 500 rpm to 1500 rpm. The formulation addition ratio for this route places the amine API at 2 wt% to 35 wt% of the dry granulate, with dry binders such as microcrystalline cellulose at 5–20 wt% and disintegrants at 2–5 wt%. Batch release is controlled under USP <905> and USP <711>, and the granulate is tested for residual water using USP <731> or equivalent pharmacopoeial method. The process is governed by 21 CFR 211.80 for component handling and 21 CFR 211.165 for release testing. Roller compaction avoids the heat and moisture exposure of wet granulation but introduces a densification history that can reduce tablet tensile strength. Production-scale failure modes include ribbon splitting at crush pressures above 25 kN/cm and granule over-lubrication when magnesium stearate is blended for more than 5 min after milling. Terminal product types are dry granulate-filled capsules, immediate-release tablets, and tablets with functional polymer coatings. This route is bounded by the need to rehydrate the granulate after compaction; if no moisture is added, the granulated material may not compress into tablets with acceptable hardness at main compression forces below 15 kN.

Lyophilization of the amine API for injectable administration begins with aseptic compounding of a buffered solution containing the active, a crystalline bulking agent, and a collapse-temperature modifier where necessary. The formulation addition ratio is defined by the clinical dose and by the solubility profile of the specific amine salt; published data for this specific configuration is limited, but development solutions commonly range from 1.0 mg/mL to 50.0 mg/mL of amine API. API-to-bulking agent mass ratios from 1:1 to 1:20 w/w are used with mannitol or glycine to create a stable cake, while cryoprotectants such as sucrose or trehalose may be added at 1–10 wt% for amorphous stabilization. The solution is filtered through a 0.22 µm sterilizing-grade filter and filled into glass vials under ISO 14644-1:2015 Grade A conditions. The freezing step ramps the shelf to -40 °C and holds the product below its glass transition or collapse temperature; annealing is performed at -15 °C to -10 °C when crystalline bulking-agent growth is needed to improve primary drying. Primary drying is run at product temperature -30 °C to -15 °C and chamber pressure 80–200 µbar, followed by secondary drying at shelf temperature 25–40 °C until residual moisture is below 1.0 wt%. The regulatory envelope for lyophilized injectables includes 21 CFR 211.167 sterility testing, USP <1> Injections, USP <85> Bacterial Endotoxins, USP <790> Particulate Matter, USP <921> Water Determination, and ISO 13408-1:2023 aseptic processing. Lyophilization cycle failure modes include cake shrinkage when shelf temperature exceeds the collapse temperature by more than 2 °C, which produces unacceptably high reconstitution time. Terminal product types include single-dose vials containing lyophilized cake for reconstitution, multi-dose vials where permitted, and lyophilized plugs intended for transfer into intravenous administration systems.

Terminal Sterilization of Aqueous Injectable Solutions in Single-Dose Vials

Aqueous injectable solutions of the amine API are processed through pH adjustment, tonicity balancing, and oxygen displacement before terminal sterilization. The formulation addition ratio is expressed as API concentration, typically from 0.5 mg/mL to 100 mg/mL depending on the salt form and its aqueous solubility at the target pH. The solution is buffered with 10–50 mM acetate, citrate, or phosphate systems, and pH is adjusted to a range compatible with both API stability and physiological tolerance, often 3.5–5.5 for amine salts; final osmolality is controlled to 250–360 mOsm/kg using sodium chloride or an isotonic polyol. Headspace oxygen is reduced by nitrogen sparging to 0.5–2.0% dissolved oxygen before filling. The solution is passed through a sterilizing-grade membrane filter with 0.22 µm pore size and filled into glass vials, after which terminally sterilized product is treated in a moist-heat autoclave at 121 °C for a cycle delivering a minimum F0 of 8–15 min. The terminal sterilization process is validated to ISO 17665-1:2006 and release testing follows USP <1>, USP <790>, and Ph. Eur. 2.9.19 particulate contamination. The manufacturing operation is controlled under 21 CFR 211.113 bioburden control and 21 CFR 211.167 sterility testing. Production-scale failures include filter blinding when the amine API is formulated below 0.5 mg/mL with inadequate surfactant or cosolvent, and vial breakage during terminal sterilization when headspace pressure exceeds ampoule or vial burst specifications. Terminal product types include single-dose vials, prefilled syringes, and glass ampoules, all filled under aseptic conditions immediately before terminal sterilization or, where necessary, under fully aseptic processing without terminal heat treatment.